Peter Johann, PhD
Dr. Johann is the founder, Chairman and CEO of Lumendi Ltd., an innovative medtech company focusing on devices enabling/improving endoluminal gastrointestinal interventions. He also is a Managing General Partner of NGN Capital, a healthcare venture capital investor. Dr. Johann had several successful IPOs and M&A transactions in his investment portfolio.
Prior to NGN he had several positions in the healthcare industry. He was the Division Head of Corporate Development at Boehringer Ingelheim where he was responsible for strategic planning, strategic projects, M&A, business development and licensing. Prior to this, Dr. Johann served at F. Hoffmann-La Roche as Global Business Leader Oncology Products, at Boehringer Mannheim as Head of Business Development and Marketing Molecular Medicine and had marketing, sales and business development responsibilities at Boehringer Mannheim Biochemicals, among others, for collaborations in the field of biopharmaceuticals. Other industry positions included Business Development Pharmaceuticals at Kaneka and Marketing and Application of Industrial Enzymes at Röhm GmbH.
Dr. Johann obtained his PhD from the Technical University Munich, Germany. He currently serves on the Board of Directors of Vivaldi Biosciences, Inc.. He previously served on the Board of Directors of Exosome Diagnostics, Inc., Noxxon Pharma AG, Micromet, Inc., Horizon Pharma, Inc., Resverlogix Corp., Zenith Epigenetics, Inc., Endosense SA, Jerini AG and NaniRx Therapeutics (later named PIN Pharma). Dr. Johann is also an advisor to LOM Medical Corp.